Biogen Inc. vs Bausch Health Companies Inc.: SG&A Expense Trends

SG&A Expense Trends: Biogen Inc. vs Bausch Health Companies Inc.

In the ever-evolving pharmaceutical industry, understanding the financial strategies of leading companies is crucial. Over the past decade, Biogen Inc. and Bausch Health Companies Inc. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Bausch Health's SG&A expenses have seen a steady increase, peaking in 2023 with a 44% rise from 2014. In contrast, Biogen's expenses have fluctuated, with a notable 14% increase in 2023 compared to 2014. This divergence highlights differing strategic priorities: Bausch Health's consistent investment in administrative functions versus Biogen's more variable approach. These trends offer insights into how each company navigates market challenges and opportunities, reflecting broader industry dynamics. As the pharmaceutical landscape continues to shift, monitoring these financial strategies will be key for stakeholders and investors alike.